{"downloaded": true, "htmlmade": false, "full": {"id": "29467192", "source": "MED", "pmid": "29467192", "pmcid": "PMC5858478", "fullTextIdList": {"fullTextId": "PMC5858478"}, "doi": "10.1182/bloodadvances.2017013391", "title": "Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia.", "authorString": "Kovacsovics TJ, Mims A, Salama ME, Pantin J, Rao N, Kosak KM, Ahorukomeye P, Glenn MJ, Deininger MWN, Boucher KM, Bavisotto LM, Gutierrez-Sanchez G, Kennedy TP, Marcus SG, Shami PJ.", "authorList": {"author": [{"fullName": "Kovacsovics TJ", "firstName": "Tibor J", "lastName": "Kovacsovics", "initials": "TJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT."}}}, {"fullName": "Mims A", "firstName": "Alice", "lastName": "Mims", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hollings Cancer Center, Medical University of South Carolina, Charleston, SC."}}}, {"fullName": "Salama ME", "firstName": "Mohamed E", "lastName": "Salama", "initials": "ME", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT."}, {"affiliation": "Department of Pathology and Associated Regional and University Pathologists Laboratories, University of Utah, Salt Lake City, UT."}]}}, {"fullName": "Pantin J", "firstName": "Jeremy", "lastName": "Pantin", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology/Oncology, Augusta University, Augusta, GA."}}}, {"fullName": "Rao N", "firstName": "Narayanam", "lastName": "Rao", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT."}}}, {"fullName": "Kosak KM", "firstName": "Ken M", "lastName": "Kosak", "initials": "KM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT."}}}, {"fullName": "Ahorukomeye P", "firstName": "Peter", "lastName": "Ahorukomeye", "initials": "P", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT."}}}, {"fullName": "Glenn MJ", "firstName": "Martha J", "lastName": "Glenn", "initials": "MJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT."}}}, {"fullName": "Deininger MWN", "firstName": "Michael W N", "lastName": "Deininger", "initials": "MWN", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT."}}}, {"fullName": "Boucher KM", "firstName": "Kenneth M", "lastName": "Boucher", "initials": "KM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Internal Medicine and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT."}}}, {"fullName": "Bavisotto LM", "firstName": "Linda M", "lastName": "Bavisotto", "initials": "LM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Porta Clinica PLLC, Seattle, WA."}}}, {"fullName": "Gutierrez-Sanchez G", "firstName": "Gerardo", "lastName": "Gutierrez-Sanchez", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Complex Carbohydrate Research Center, University of Georgia, Athens, GA."}}}, {"fullName": "Kennedy TP", "firstName": "Thomas P", "lastName": "Kennedy", "initials": "TP", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Pulmonary Medicine, Wake Forest University, Winston-Salem, NC; and."}}}, {"fullName": "Marcus SG", "firstName": "Stephen G", "lastName": "Marcus", "initials": "SG", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Cantex Pharmaceuticals, Weston, FL."}}}, {"fullName": "Shami PJ", "firstName": "Paul J", "lastName": "Shami", "initials": "PJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT."}}}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "4", "volume": "2", "journalIssueId": "2652153", "dateOfPublication": "2018 Feb", "monthOfPublication": "2", "yearOfPublication": "2018", "printPublicationDate": "2018-02-01", "journal": {"title": "Blood advances", "ISOAbbreviation": "Blood Adv", "medlineAbbreviation": "Blood Adv", "NLMid": "101698425", "ISSN": "2473-9529", "ESSN": "2473-9537"}}, "pubYear": "2018", "pageInfo": "381-389", "abstractText": "Relapses in acute myelogenous leukemia (AML) are a result of quiescent leukemic stem cells (LSCs) in marrow stromal niches, where they resist chemotherapy. LSCs employ CXCL12/CXCR4 to home toward protective marrow niches. Heparin disrupts CXCL12-mediated sequestration of cells in the marrow. CX-01 is a low-anticoagulant heparin derivative. In this pilot study, we combined CX-01 with chemotherapy for the treatment of AML. Induction consisted of cytarabine and idarubicin (7 + 3) with CX-01. Twelve patients were enrolled (median age, 56 years; 3 women). Three, 5, and 4 patients had good-, intermediate-, and poor-risk disease, respectively. Day 14 bone marrows were available on 11 patients and were aplastic in all without detectable leukemia. Eleven patients (92%) had morphologic complete remission after 1 induction (CR1). Eight patients were alive at a median follow-up of 24 months (4 patients in CR1). Three patients received an allogeneic stem cell transplant in CR1. Median disease-free survival was 14.8 months. Median overall survival was not attained at the maximum follow-up time of 29.4 months. No CX-01-associated serious adverse events occurred. Median day to an untransfused platelet count of at least 20\u2009\u00d7\u2009109/L was 21. CX-01 is well tolerated when combined with intensive therapy for AML and appears associated with enhanced count recovery and treatment efficacy.", "affiliation": "Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print", "pubTypeList": {"pubType": ["Clinical Trial", "Research Support, Non-U.S. Gov't", "research-article", "Multicenter Study", "Journal Article"]}, "grantsList": {"grant": {"grantId": "R01 CA178397", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Heparin", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Anticoagulants", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Agents", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Drug Therapy, Combination", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Survival Analysis"}, {"majorTopic_YN": "N", "descriptorName": "Pilot Projects"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Leukemia, Myeloid, Acute", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Young Adult"}]}, "chemicalList": {"chemical": [{"name": "Anticoagulants", "registryNumber": "0"}, {"name": "Antineoplastic Agents", "registryNumber": "0"}, {"name": "Heparin", "registryNumber": "9005-49-6"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/bloodadvances.2017013391"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5858478"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5858478?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/bloodadvances.2017013391"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "12", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-02-04", "dateOfCreation": "2018-02-23", "firstIndexDate": "2018-02-23", "fullTextReceivedDate": "2020-07-10", "dateOfRevision": "2019-02-15", "firstPublicationDate": "2018-02-01"}, "abstract": "Relapses in acute myelogenous leukemia (AML) are a result of quiescent leukemic stem cells (LSCs) in marrow stromal niches, where they resist chemotherapy. LSCs employ CXCL12/CXCR4 to home toward protective marrow niches. Heparin disrupts CXCL12-mediated sequestration of cells in the marrow. CX-01 is a low-anticoagulant heparin derivative. In this pilot study, we combined CX-01 with chemotherapy for the treatment of AML. Induction consisted of cytarabine and idarubicin (7 + 3) with CX-01. Twelve patients were enrolled (median age, 56 years; 3 women). Three, 5, and 4 patients had good-, intermediate-, and poor-risk disease, respectively. Day 14 bone marrows were available on 11 patients and were aplastic in all without detectable leukemia. Eleven patients (92%) had morphologic complete remission after 1 induction (CR1). Eight patients were alive at a median follow-up of 24 months (4 patients in CR1). Three patients received an allogeneic stem cell transplant in CR1. Median disease-free survival was 14.8 months. Median overall survival was not attained at the maximum follow-up time of 29.4 months. No CX-01-associated serious adverse events occurred. Median day to an untransfused platelet count of at least 20\u2009\u00d7\u2009109/L was 21. CX-01 is well tolerated when combined with intensive therapy for AML and appears associated with enhanced count recovery and treatment efficacy.", "journaltitle": "Blood advances", "authorinfo": ["Kovacsovics TJ", "Mims A", "Salama ME", "Pantin J", "Rao N", "Kosak KM", "Ahorukomeye P", "Glenn MJ", "Deininger MWN", "Boucher KM", "Bavisotto LM", "Gutierrez-Sanchez G", "Kennedy TP", "Marcus SG", "Shami PJ"], "title": "Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia."}